AVECTAS partners with NIBRT to lead €7.23 million Consortium Awarded Part Funding From Disruptive Technologies Innovation Fund

Irish cell engineering company Avectas is leading a consortium which will invest €7.23m, including €4.4m awarded under the Disruptive Technology Innovation Fund, to develop its proprietary cell engineering platform Solupor.

With consortium partners Bluebridge Technologies and NIBRT, the project expands its development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture ‘off-the-shelf’ cell-based therapies for cancer treatment.

You can read the full press release here: https://lnkd.in/eW5eaR5

RTE Coverage: https://lnkd.in/e2HP3eq